Acitretin, a retinol derivative, was introduced in 1989 for the
treatment of severe psoriasis. By the end of 1990, acitretin was confirmed to be
metabolized in part to etretinate. Marketing authorization was suspended
temporarily in France while the product information was modified to conform to the
recommendations issued by the Committee for Proprietary Medicinal Products of
the European Communities. Acitretin remains registered in several countries. See
also WHO comment for etretinate.
All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.